EUVIMEDEUVIMED entdecken
Crossref

Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1701a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Pyridazines, Uracil. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resmetirom (Rezdiffra – Madrigal), a thyroid hormone receptor-beta agonist, has received accelerated approval from the FDA for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseasePyridazinesUracilAnimalsHumansFatty LiverDrug Approval

Stichwörter der Autor:innen

MASHRezdiffraadverse effectsdosagedrug interactionsefficacylactationpregnancyresmetiromsafetysteatohepatitis

Substanzen

resmetiromPyridazinesUracil

Zitieren

APA

(2024). Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1701a

Vancouver

Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1701a

BibTeX
@article{euvimed2024,
  title = {Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1701a}
}
Kostenlos starten →